. 2022 Sep 28;11(19):5742. doi: 10.3390/jcm11195742

Table 2.

Predictive factors associated with serum-urate levels < 6.0 mg/dL at a visit in a referral centre.

	Univariate OR (95% CI)	Multivariate OR (95% CI)
Gout duration (years)	0.996 (0.95–1.04)	-
No ULT at baseline	1.38 (0.69–2.77)	-
Alcohol/sweetened-beverage consumption - No consumption - Former - Current	- 0.69 (0.21–2.29) 1.12 (0.52–2.39)	- - -
Ethnicity - Caucasian - North African - Sub Saharan African - Other	- 0.81 (0.31–2.12) 0.38 (0.12–1.15) ^a 0.36 (0.11–1.17)	- - - -
Body-mass index at baseline (kg/m²)	0.995 (0.93–1.07)	-
High blood pressure	1.47 (0.74–2.95)	-
Major cardiovascular event	0.99 (0.46–2.12)	-
Diabetes mellitus	1.24 (0.58–2.64)	-
Congestive heart failure	0.77 (0.26–2.32)	-
Dyslipidaemia	1.13 (0.55–2.31)	-
Hepatopathy	0.39 (0.07–2.05)	-
Number of gout complications at baseline	1.09 (0.77–1.55)	-
Ultrasound/subcutaneous tophi	2.63 (1.20–5.74) ^b	3.00 (0.99–9.08)
Double contour sign identified with joint ultrasound	0.68 (0.32–1.48)	-
DECT MSU deposits at baseline	0.73 (0.22–2.43)	-
Age at gout onset (per year)	1.03 (1.01–1.06) ^b	1.04 (1.00–1.08)
Age at baseline (per year)	1.03 (1.01–1.06) ^b	-
Good compliance to ULT prior to visit:	35.36 (5.46–229.08) ^d	-
ULT: - No ULT or ULT different from ALLO/FBX or ALLO < 300 mg/d or FBX < 80 mg/d - ALLO ≥ 300 mg/d or FBX ≥ 80 mg/d	- 9.74 (3.87–24.53) ^d	- 7.49 (2.17–25.9) ^c
Hyperuricaemic therapy added to the patient’s background treatment since last visit	0.78 (0.24–2.58)	-
Hyperuricaemic therapy removed from the patient’s background treatment since last visit	0.29 (0.07–1.10) ^a	0.18 (0.027–1.22)
ULT switch at previous visit	0.83 (0.17–4.02)	-

p-value significance set at 0.05: ^ap < 0.2, ^b p < 0.05, ^c p < 0.01, ^d p < 0.001; OR: odds ratio; CI: confidence interval; ALLO: allopurinol; FBX: febuxostat; ULT: urate-lowering therapy; DECT: dual-energy computed tomography; MSU: monosodium urate.